# A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

> **NCT05868356** · PHASE1 · COMPLETED · sponsor: **Mirati Therapeutics Inc.** · enrollment: 18 (actual)

## Conditions studied

- Healthy Adults

## Interventions

- **DRUG:** Treatment A
- **DRUG:** Treatment B

## Key facts

- **NCT ID:** NCT05868356
- **Lead sponsor:** Mirati Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-06-01
- **Primary completion:** 2023-07-25
- **Final completion:** 2023-08-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05868356

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05868356, "A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT05868356. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*